Opinion|Videos|October 21, 2024
The Benefits of a Multidisciplinary Approach to Managing Prostate Cancer
Key Takeaways
- Androgen deprivation therapy remains fundamental, but resistance necessitates additional treatments like androgen receptor signaling inhibitors.
- Chemotherapy, especially docetaxel, is combined with ADT for improved outcomes in specific patient groups.
Panelists discuss how the landscape of treatment options for advanced prostate cancer has evolved, highlighting the importance of understanding current therapies to optimize patient outcomes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Can you provide an overview of the current treatment options for advanced prostate cancer and how they’ve evolved?
Advertisement
Related to this article
Irene Flores' advocacy for bedside nurses helped build a local stem cell transplant program, making her an Extraordinary Healer Award nominee.
Lunsumio added to Revlimid kept relapsed or refractory follicular lymphoma from worsening longer than Rituxan plus Revlimid in the phase 3 CELESTIMO trial.
Three new studies from WCLC 2026 show strong results in ROS1-positive NSCLC, EGFR-mutant NSCLC and relapsed small cell lung cancer, offering fresh options.
See 5 years of FDA leukemia approvals for CLL, AML and CML — new drugs, new drug classes, and how many patients they've actually helped.
Phase 2 findings on divesiran point to a potential way to control hematocrit while reducing repeated blood draws for those living with polycythemia vera, like Nona Baker.
Four of seven patients had no visible cancer on scans in early data from CONVERGE, a trial testing a tumor injection meant to boost radiation in lung cancer.
FDA approves Inluriyo plus Verzenio for adults with ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy.
September is Blood Cancer Awareness Month, and the pipeline for leukemia, lymphoma and myeloma is as active as it has been in years.
Advertisement
Advertisement